| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease : a comprehensive review by EURECA-m and ERBP working groups of ERA
Authors:ID Mark, Patrick B. (Author)
ID Sarafidis, Pantelis (Author)
ID Ekart, Robert (Author)
ID Ferro, Charles J. (Author)
ID Balafa, Olga (Author)
ID Fernandez-Fernandez, Beatriz (Author)
ID Herrington, William G. (Author)
ID Rossignol, Patrick (Author)
ID Del Vecchio, Lucia (Author)
ID Valdivielso, Jose M. (Author)
Files:.pdf Mark-2023-SGLT2i_for_evidence-based_cardiorena.pdf (1,05 MB)
MD5: EF111EB4B346D1C36983E41A12B96796
 
URL https://doi.org/10.1093/ndt/gfad112
 
Language:English
Work type:Scientific work
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Abstract:Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits—on a relative scale—appear similar in patients with or without diabetes. Specialty societies’ guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.
Keywords:cardiorenal syndrome, cardiovascular, chronic renal failure, diabetic kidney disease, heart failure
Publication status:Published
Publication version:Version of Record
Publication date:25.05.2023
Publisher:Oxford University Press
Year of publishing:2023
Number of pages:Str. 2444-2455
Numbering:Letn. 38, Št. 11
PID:20.500.12556/DKUM-86979 New window
UDC:616.6
ISSN on article:1460-2385
COBISS.SI-ID:155795971 New window
DOI:10.1093/ndt/gfad112 New window
Publication date in DKUM:21.02.2024
Views:241
Downloads:14
Metadata:XML DC-XML DC-RDF
Categories:Misc.
:
MARK, Patrick B., SARAFIDIS, Pantelis, EKART, Robert, FERRO, Charles J., BALAFA, Olga, FERNANDEZ-FERNANDEZ, Beatriz, HERRINGTON, William G., ROSSIGNOL, Patrick, DEL VECCHIO, Lucia and VALDIVIELSO, Jose M., 2023, SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease : a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrology dialysis transplantation [online]. 2023. Vol. 38, no. Št. 11, p. 2444–2455. [Accessed 22 January 2025]. DOI 10.1093/ndt/gfad112. Retrieved from: https://dk.um.si/IzpisGradiva.php?lang=eng&id=86979
Copy citation
  
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Nephrology dialysis transplantation
Shortened title:Nephrol. dial. transplant.
Publisher:Oxford University Press
ISSN:1460-2385
COBISS.SI-ID:3510449 New window

Document is financed by a project

Funder:Other - Other funder or multiple funders
Project number:PI18/01366

Funder:Other - Other funder or multiple funders
Project number:PI19/00588

Funder:Other - Other funder or multiple funders
Project number:PI19/00815

Funder:Other - Other funder or multiple funders
Project number:PI21/00251

Funder:Other - Other funder or multiple funders
Project number:PI20/00744

Funder:Other - Other funder or multiple funders
Project number:AC18/00064
Name:KIDNEY ATTACK

Funder:Other - Other funder or multiple funders
Project number:AC18/00064

Funder:Other - Other funder or multiple funders
Project number:RD016/0009
Acronym:ISCIII-RETIC REDinREN

Funder:Other - Other funder or multiple funders
Project number:B2017/BMD-3686
Acronym:CIFRA2-CM

Funder:Other - Other funder or multiple funders
Project number:RICORS2040
Name:RICORS programme

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:25.05.2023

Secondary language

Language:Slovenian
Keywords:kardiorenalni sindrom, kardiovaskularno, odpoved ledvic, diabetična ledvična bolezen, srčno popuščanje


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica